A Phase 3 trial, randomized, open-label, 2-period crossover study to evaluate the safety and efficacy of SHP655 in the treatment and prevention of acute TTP events in patients with severe hereditary ADAMTS13 deficiency.
Phase of Trial: Phase III
Latest Information Update: 24 Mar 2017
At a glance
- Drugs BAX 930 (Primary)
- Indications Thrombotic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
- 24 Mar 2017 New trial record